Daratumumab is effective in the relapsed or refractory systemic light-chain amyloidosis but associated with high infection burden in a frail real-life population.
Van de Wyngaert Z, Carpentier B, Pascal L, Lionne-Huyghe P, Leduc I, Srour M, Vasseur M, Demarquette H, Terriou L, Herbaux C, Manier S, Bossard JB, Barbieux S, Chauvet P, Willaume A, Nudel M, Bories C, Gibier JB, Facon T, Boyle EM.
Van de Wyngaert Z, et al. Among authors: vasseur m.
Br J Haematol. 2020 Feb;188(3):e24-e27. doi: 10.1111/bjh.16282. Epub 2019 Nov 19.
Br J Haematol. 2020.
PMID: 31742668
Free article.
Clinical Trial.
No abstract available.